New drug for type 2 diabetes is no better than older, cheaper treatments, says instituteBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e8593 (Published 19 December 2012) Cite this as: BMJ 2012;345:e8593
- Ned Stafford
The agency responsible for evaluating the effectiveness of drugs in Germany has for a second time concluded that linagliptin, a new drug used to treat type 2 diabetes, offers no added benefit over older, less expensive treatments already on the market.1
The agency, the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Healthcare), widely known as IQWIG, is evaluating linagliptin as part of a complex process to determine the reimbursement price paid by Germany’s public health insurance system to drug companies to cover the cost of treatment with the drug.
Linagliptin was approved …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial